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Abstract
Background: Endometrial cancer is the most common gynecologic malignancy in developed countries and little is known
about the underlying mechanism of stage and disease outcomes. The goal of this study was to identify differentially
expressed genes (DEG) between late vs. early stage endometrioid adenocarcinoma (EAC) and uterine serous carcinoma
(USC), as well as between disease outcomes in each of the two histological subtypes.
Methodology/Principal Finding: Gene expression profiles of 20 cancer samples were analyzed (EAC=10, USC=10) using
the human genome wide illumina bead microarrays. There was little overlap in the DEG sets between late vs. early stages in
EAC and USC, and there was an insignificant overlap in DEG sets between good and poor prognosis in EAC and USC.
Remarkably, there was no overlap between the stage-derived DEGs and the prognosis-derived DEGs for each of the two
histological subtypes. Further functional annotation of differentially expressed genes showed that the composition of
enriched function terms were different among different DEG sets. Gene expression differences for selected genes of various
stages and outcomes were confirmed by qRT-PCR with a high validation rate.
Conclusion: This data, although preliminary, suggests that there might be involvement of distinct groups of genes in tumor
progression (late vs. early stage) in each of the EAC and USC. It also suggests that these genes are different from those
involved in tumor outcome (good vs. poor prognosis). These involved genes, once clinically verified, may be important for
predicting tumor progression and tumor outcome.
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Introduction
Endometrial cancer is the most common gynecologic malig-
nancy in developed countries, including an estimated 42,160 new
cases in the United States in 2009 and claiming almost 7,780 lives
[1]. Based on clinico-pathologic and molecular data, endometrial
adenocarcinomas are dichotomized into two types: type I,
endometrioid adenocarcinoma (EAC) and mucinous adenocarci-
noma; type II, uterine serous carcinoma (USC) and clear cell
carcinoma (CCC) [2]. EACs are the most frequent subtype and
account for more than 80% of all endometrial adenocarcinomas.
They are associated with obesity, exogenous hormonal therapy
and they tend to present as low grade, early stage tumors with
good outcomes, often cured with surgery alone. However,
approximately 11% to 16% of women with EAC will present
with FIGO (International Federation of Gynecology and Obstet-
rics) stage II, III and stage IV disease with 5-year survival rate of
70%, 40–50% and 15–20% respectively. USCs account for 3–
10% of endometrial carcinomas. While USCs represent a minority
of total endometrial cancer cases they are responsible for a
disproportionate number of deaths [3,4]. They are high grade
tumors with deep myometrial invasion and lymphovascular
involvement [5]. The 5-year survival rates are estimated to be
50% for stage II, 20% for stage III and 5–10% for stage IV disease
[6].
Molecular genetic data supports the idea that endometrial
carcinomas are likely to develop through a multi-step process of
oncogene activation and tumor suppressor gene inactivation. In
addition, studies have demonstrated that molecular alterations are
specific for type I and type II endometrial carcinoma. Type I
cancer is characterized by mutation of PTEN, and defects in DNA
mismatch repair (as evidenced by the microsatellite instability
phenotype) [7,8]. Type II cancers are characterized by p53 and
Her-2/neu mutations [9,10]. However, these gene alterations
alone do not explain the different behavior and outcomes in type I
and type II cancers. Most of the studies using cDNA microarray
analysis have only focused on defining differential gene expression
among different histologic types of endometrial cancer [11–17].
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15415The aims of this study were focused on stages and outcomes in two
histologic types: EAC and USC. The purpose was to identify the
difference in gene expression patterns in late stages (stage III and
IV) versus early stages (stage I and II) in each of the two types and
in patients with good prognosis versus poor prognosis in EAC and
USC, respectively.
Results
Comparison of Stages and Outcomes
Under the framework of linear model, we inferred the
differential expression based on the following collected patients’
characteristics: EAC stage (late n=5 vs. early n=5), USC stage
(late n=5 vs. early n=5), EAC prognosis (good n=6 vs. poor
n=4), and USC prognosis (good n=6 vs. poor n=4). The number
of identified DEGs and the subgroup restricted by desired fold
change for each comparison are illustrated in Table S1. A direct
comparison of their total gene expression patterns was performed
to evaluate the differences among each category.
Hierarchical clustering of patients samples based on DEGs
(p,0.01) obtained from comparing late vs. early stage in USC
group and EAC group, respectively, is illustrated in Figure 1. We
identified 274 DEGs at significance level (p,0.01) in patients with
USC, with 165 genes up-regulated and 109 genes down-regulated
in late stage disease. The 274 DEGs separate the 5 USC late stage
patients from the 5 USC early stage patients. For stage comparison
(late vs. early) in patients with EAC, we identified 111 significant
DEGs (p,0.01), with 92 genes up-regulated and 19 genes were
down-regulated in late stages. The 111 DEGs accurately separate
the 5 EAC late stage patients from the 5 EAC early stage patients.
For prognosis comparison (good vs. poor), we identified 135 and
112 DEGs at a significance level (p,0.01), for USC and EAC
respectively (Figure 2). The 112 DEGs derived from good vs. poor
prognosis comparison in EAC subtype accurately separate the 6
EAC good prognosis patients from the 4 EAC poor prognosis
patients. Although less perfect, the 135 DEGs derived from good
vs. poor prognosis comparison in USC subtype can separate 5 of
the 6 USC good prognosis patients from the 4 USC poor
prognosis patients.
The complete list of DEGs with at least 2-fold change from the
four separate comparisons described above is listed in Table S2–S5.
To compare the tumor progression mechanism level between
different endometrial adenocarcinoma subtypes (USC vs. EAC) at
the transcriptome level, we first examined the overlap between
stage-derived DEGs in USC and stage-derived DEGs in EAC. As
shown in Figure 3, we found that there is minimal overlap between
the two DEG sets. Only 4 DEGs are shared by the 274 stage-
derived DEGs in USC and the 111 stage-derived DEGs in EAC.
There is no overlap when two-fold change is included as the
restriction.
We then evaluated the overlap between prognosis-derived
DEGs in USC and prognosis-derived DEGs in EAC. As shown in
Figure 3 we found that there is minimal overlap between the two
DEG sets. Only 1 DEG is shared by the 135 prognosis-derived
DEGs in USC and the 112 prognosis-derived DEGs in EAC.
Figure 4 illustrates the overlap between stage-derived DEGs and
prognosis-derived DEGs in both USC and EAC subtypes.
Remarkably, we found no overlap between stage-derived DEGs
and prognosis-derived DEGs in both subtypes. For USC, the 274
stage-derived DEGs are distinct from the 135 prognosis-derived
DEGs, and for EAC, the 111 stage-derived DEGs are distinct from
the 112 prognosis-derived DEGs.
The lack of overlap between stage-related (late vs. early) and
prognosis-related (good vs. poor) DEG sets in each subtype is of
particular interest. This suggests that it might be necessary to
identify and develop separate diagnosis biomarkers for endome-
trial adenocarcinoma stage diagnosis and patient outcome
prediction.
Further functional annotation of DEGs showed that the
composition of enriched function terms were different between
Figure 1. Hierarchical clustering of patient samples based on differentially expressed genes (P,0.01) obtained from comparing
late stage versus early stage in the USC group and EAC group, respectively. A) USC group. B) EAC group. In clustering dendrogram, blue
stands for early stage samples while yellow stands for late stage samples. Red means up-regulated while green means down regulated.
doi:10.1371/journal.pone.0015415.s001.g001
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good prognosis versus poor prognosis in the USC group and EAC group, respectively. A) USC group. B) EAC group. In clustering
dendrogram, blue stands for good prognosis samples while yellow stands for poor prognosis samples. Red means up-regulated while green means
down regulated.
doi:10.1371/journal.pone.0015415.s001.g002
Figure 3. Venn diagrams show little overlap for DEGs derived from the USC and EAC groups, respectively. Left) DEGs from comparing
late stage versus early stage in the USC group and EAC group, respectively. Right) DEGs from comparing good prognosis versus poor prognosis in the
USC group and EAC group, respectively. A) DEGs as defined by P-value,0.01. B) DEGs with at least 1.5-fold change. C) DEGs with at least 2-fold
change.
doi:10.1371/journal.pone.0015415.s001.g003
Gene Expression in Endometrial Carcinoma
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enriched function terms in USC group are nucleic metabolism,
protein traffic and cell cycle, while the most enriched function
terms in EAC group are cell structure and mobility, amino acid
metabolism and fatty acid metabolism. For outcome-related
DEGs, the most enriched function terms in USC group are
nucleic metabolism and mRNA transcription, while the most
enriched function terms in EAC group are developmental process.
Remarkably, the only overlapped function term is nucleic
metabolism which is enriched in both stage-related and out-
come-related DEGs of USC group. This suggests that different
tumor histology, stage and disease outcomes in endometrial
adenocarcinoma might involve either different pathways or
different components of common pathways. However, these
results should be interpreted with caution given the relatively
small sample size, and a larger group in future study will be needed
for validations.
qRT-PCR Validation of Microarray Data
We randomly selected 18 differentially expressed genes with at
least 2-fold change identified by microarray for validation by
quantitative Real Time PCR (qRT-PCR). Selected genes include
those up-regulated in late vs. early USC (LPAR2 and EPHA1), as
well as in EAC (CNTN1, ELF5, KIF14 and TFF3) and those they
were down-regulated in late vs. early USC (RPRM, NME3,
NR2F1), as well as in EAC (HOXD10). The selected genes also
include those up-regulated in good vs. poor diagnosis in USC
(RHOBTB3, CEBPA) as well as in EAC (FBLN1, APLNR), and
those down-regulated in good vs. poor diagnosis in USC (FOSB,
RASSF7) as well as in EAC (FST, LMO4). qRT-PCR data of 15
genes indicated at least 2-fold change in expression levels and were
concordant with the microarray data, yielding a validation rate of
15/18. Three genes, FST, LMO4 and RPRM, have less than 2-fold
change in expression level based on qRT-PCR. However, their
directions of expression change estimated by qRT-PCR are
consistent with those estimated from microarray (Figure 6).
Discussion
The main focus of the study is to identify and evaluate gene
expression patterns in late vs. early stage and good vs. poor
prognosis in each of endometrioid and serous types. Using the
Illumina HumanHT-12 v3 microarray, we found 274 and 111
stage-related DEG in each of USC and EAC respectively.
However, we were not able to find any overlap for DEGs with
at least 2 fold changes in late stages EAC and USC versus early
stages EAC and USC, indicating that tumor progression of
different endometrial adenocarcinoma subtypes might be charac-
terized by distinct gene expression signatures. In addition, we
found 112 DEGs that are differently expressed for good vs. poor
prognosis in EAC and 135 DEGs in USC. Only 1 DEGs is shared
by the 135 prognosis-derived DEGs in USC and the 112
prognosis-derived DEGs in EAC. These findings indicate that
tumor outcome of different endometrial adenocarcinoma subtypes
might also characterized by distinct gene expression signatures. In
other words, DEGs derived from USC might exclusively contain
USC-specific prognosis biomarkers, while the DEGs derived from
EAC might exclusively contain EAC-specific prognosis biomark-
ers. This confirms the existence of a distinct gene expression
signature between endometrioid and serous carcinoma as
previously seen [11,15,16], and that there is a distinct gene
expression signature driving late vs. early stages in each of these
two types. Additionally, the lack of overlap between stage-related
and prognosis-related DEG sets in each subtype is of particular
interest suggesting genes that drive and control stages might be
distinct from the genes that drive and control outcomes. As a
result, it would be of paramount interest to identify tailored
biomarkers for outcome prediction and treatment modalities in
patients with endometrial adenocarcinoma. Clearly, given the
relatively small sample size, these findings should be interpreted
with caution and a larger cohort is needed to validate these
findings.
Reviewing the microarray data on endometrial adenocarcino-
mas, there were a few DEGs that have previously been described
in literatures and confirmed in this study [11–17]. For example,
Ephrin receptor A1 (EphA1), located at 7q32-q36, is a novel receptor
tyrosine kinase gene. The EphA1receptor/ephrin ligand system
has been implicated in tumor progression in a number of
malignancies where they are strongly involved in tumorigenesis
including metastatsis, angiogenesis and invasion [11,18–20]. Trefoil
factor 3 (TFF3), located at 21q22.3, belongs to a family of small
mucin-associated polypeptides that can regulate cancer progres-
sion by increasing tumor metastasis [16,17,21,22]. E74-like factor 5
(ELF5) or epithelium –specific ETS factor 2 (ESE2), located at 11p15-
p13, is a member of the ETS family of transcription factors and
has been implicated to play a key role in cell proliferation,
differentiation, apoptosis and tumorigenesis [17,23].
However, a number of the DEGs identified in our study
represent novel ones, not captured by previous studies. For
example, lysophosphatidic acid receptor 2 (LPAR2), mapped at 19p12
locus, is an important extracellular signaling molecule that
mediates a wide range of actions such as cell proliferation, cell
survival, migration, adhesion, and angiogenesis. Recently, LAPR2
was found to be overexpressed in ovarian tumors and authors have
speculated that this gene may contribute to the initiation,
Figure 4. Venn diagrams show no overlap between stage-
related DEGs (late versus early) and outcome-related DEGs
(good versus poor) in both USC and EAC groups. EvL means
DEGs from comparing late stage versus early stage patients. GvB means
DEGs from comparing good prognosis versus poor prognosis patients.
A) DEGs as defined by P-value,0.01 in USC group. B) DEGs as defined
by P-value,0.01 in EAC group.
doi:10.1371/journal.pone.0015415.s001.g004
Gene Expression in Endometrial Carcinoma
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our data, LAPR2 could be possibly be an indicator of late stage
USC and thus causing aggressive tumor behavior. Other novel
DEGs that were found to be over-expressed in late vs. early EAC
are Contactin 1 (CNTN1) at 12q11-q12 and kinesin family member 14
(KIF14) or KIAA0042 mapped at 1q31 locus. Contactin- 1 is a
metastasis promoter gene that plays an essential role in tumor
metastasis and tumor invasion. In animal studies, knockdown
contactin-1 resulted in inhibition of tumor metastasis and an
increase in survival. In patients with lung adenocarcinoma, high
Contactin-1 expression was directly correlated with tumor stage,
lymph node metastasis and poor survival [29]. Minimal literature
has been published regarding its mechanism; therefore, inhibitors
of contactin-1 could be a possible target therapy in advanced stage
EAC. Over-expression of KIF14 by RT-PCR was seen in
retinoblastoma and numerous other cancer types including breast,
lung, larynx, and hepatocellular carcinoma where numerous
studies suggested that KIF14 might have oncogenic potential [30–
32]. Although its cellular function is not clear, KIF14 belongs to
the kinesin family and it usually plays an important role in mitosis.
Its expression was a predictor of tumor grade and a decreased
disease-free survival rate in breast cancer [33]. In our study, the
over-expression of KIF14 is an indicator of advanced, late stage
EAC. Among the genes under-expressed in late vs. early stages
USC, we found nonmetastatic cells 3 (NME3) located at 16q13,
and nuclear receptor subfamily 2 or transcription factor COUP-1
(NR2 F1/ COUP- TF1) gene, which is mapped at 5q14 locus.
NME3 is a member of the nm23 putative suppressor gene family
associated with metastasis, differentiation and apoptosis of cancer
cells [26]. In our study, the finding of NME3 under-expression in
Figure 5. Enriched function annotation of differentially expressed genes (P,0.01) identified by microarray. Enriched functional
annotations are reported by NCBI DAVID API server with default setting. The number following each enriched functional term is the number of
annotated DEGs. A) Enriched functional annotation for stage-related DEGs (late versus early) in USC group. B) Enriched functional annotation for
stage-related DEGs in EAC group. C) Enriched functional annotation for outcome-related DEGs (good versus poor) in USC group. D) Enriched
functional annotation for outcome-related DEGs in EAC group.
doi:10.1371/journal.pone.0015415.s001.g005
Gene Expression in Endometrial Carcinoma
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metastasis suppressor. NR2F1, also known as COUP TF1,i s
chicken ovalbumin upstream promoter transcription factor
(member of the orphan steroid receptor superfamily). Studies
showed the involvement of COUP-TF1 in cell differentiation and
growth in endometrial and ovarian cancer cells [27]. Recently, this
gene was found to play a role in lymphangeogenesis via regulation
of the vascular endothelial growth factor (VEGF) in cancer [28].
HOXD10 belongs to the HOX regulatory family of genes that
encode transcription factors which are essential during embryonic
development [34]. HOX genes are important for human
endometrial development and receptivity. HOXD10 was found to
be strongly expressed in normal human uterine tissue. The
expression of HOXD10 was extremely reduced in endometrial
carcinoma especially in high grade tumors, suggesting that it could
have a role in oncogenesis [35].
RHO-related BTB domain-containing protein3 (RHOBTB3) or
also known as KIAA0878 has been mapped on 5q14.3 locus and
the gene has been differentially expressed and confirmed by qRT-
PCR in good vs.poor USC outcome. RhoBTB3 is a member of the
RHOBTB subfamily of Rho GTPases that play a role in mediating
cell size, proliferation, apoptosis, survival, polarity, call adhesion
and membrane trafficking [36]. Recent studies have suggested that
RhoB is involved in tumor suppression. These studies suggested
that RhoB was detected in normal tissue yet its expression was
dramatically lost during cancer progression in lung and head and
neck squamous cell carcinoma [37,38]. In line with these findings,
high expression of RhoB was associated with favorable outcome in
bladder cancer. In our study, we suggested that RhoBTB3 might
serve as a potential tumor marker for good prognosis in USC.
RAS association domain family 7 (RASSF7) is located at 11p15.5
and it belongs to the Ras-domain family of ten members that are
implicated in various cellular mechanisms including apoptosis, cell
cycle control, and microtubule stabilization [39]. They are down-
regulated by epigenetic mechanisms, indicating the potential role
of a tumor suppressor gene. However, this does not currently exist
in RASSF7 [40]. Recently RASSF7 was found in numerous tissues
and knocking down RASSF7 function resulted in blocking spindle
formation, triggering a mitotic arrest, nuclear breakdown and
apoptosis. This suggests the possibility that RASSF7 could have a
role in promoting cancer cell development [41]. In our study the
under-expression of RASSF7 in USC correlated with good
prognosis and the detection of RASSF7 silencing by methylation
study could have potential clinical use for USC prognosis and
treatment. Finally, Fibulin1 (FBLN1), mapped on 22q13.3 gene,
belongs to a family of secreted glycoproteins. Fibulin family has
Figure 6. qRT-PCR validation of differentially expressed genes (P,0.01) with at least two-fold expression change as identified by
microarray. A) stage-related DEGs (late versus early) in USC group. B) stage-related DEGs in EAC group. C) Outcome-related DEGs (good versus poor)
in USC group. D) Outcome-related DEGs in EAC group. Blue bar is the fold change estimated by qRT-PCR, while red bar is the fold change estimated
by microarray. The fold change is shown in log2 scale (i.e., .1 means at least 2-fold up, while ,21 means at least 2-fold down). The three genes with
less than two-fold change in expression level based on qRT-PCR are FST, LMO4 and RPRM.
doi:10.1371/journal.pone.0015415.s001.g006
Gene Expression in Endometrial Carcinoma
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motility. In particular, FBLN1 appeared to have a role in inhibiting
cell adhesion, spreading, motility and invasion in human cancer
cells [42]. In vivo studies showed increased FBLN1 expression in
ovarian and breast carcinomas. Others had showed its down-
regulation in prostate and gastric cancer [43]. Therefore,
speculation still exists regarding FBLN1 as a tumor-suppressor
gene or an oncogene or it might even have dual functions [44]. In
our study, the over-expression of the FBLN1 protein was observed
for good prognosis in EAC.
One limitation of this study is the relatively small sample size
which does not provide us enough power for statistical analysis of
expression levels of DEGs and clinical characteristics. The result
should be interpreted with caution because of the small sample size
and undetermined molecular mechanisms of novel DEGs.
Nevertheless, novel DEGs found in our studies, once narrowed
down and verified in future studies with larger cohort, might have
potential prognostic and therapeutic effects in each of EAC and
USC.
In conclusion, although the sample size was small for a definite
conclusion, we believe that our findings shed meaningful insights
into the clinical study of endometrial cancer patients that warrant
further investigation. Future large studies and advanced technol-
ogies are warranted to confirm our findings and further explore
the potential of DEGs to be utilized clinically as novel biomarkers
for endometrial cancer.
Materials and Methods
Tissue Specimens
Flesh-frozen cancer specimens were obtained from 20 patients
undergoing surgery for uterine cancer at Roswell Park Cancer
Institute (RPCI) including 10 cases of EAC, and 10 cases of USC.
Five out of 10 EAC specimens were from patients with early stage
disease (FIGO stage I and II), and five specimens were from
patients with late stage (FIGO stage III and IV). Of these 5 early
stage EAC, 3 had good outcome and 2 had poor outcome.
Similarly, 3 late stage EAC had a good prognosis and 2 had a poor
prognosis. The same patient distribution was for USC cases. All of
the tissue samples were collected under an Institutional Review
Board-approved protocol at RPCI. The hematoxylin-eosin (HE)
slides were reviewed by one Pathologist to confirm the tumor
subtype and FIGO grade. All patients were treated per National
Comprehensive Cancer Network guidelines [45]. Patients’ charts
were reviewed for patient follow-up which ranged from 18 months
to 60 months. Good prognosis is defined as patients who are alive
with no evidence of disease at last follow-up. Poor prognosis is
defined as patients who are alive with recurrent disease,
persistence, or progression of disease as well as patients who died
from disease. The Health Sciences Institutional Review Board
(HSIRB) of Roswell Park Cancer Institute has authorized this
research.
Sample Processing and Gene Expression Profiling
RNA preparation. The fresh frozen tissues were cut and
examined to make certain that the tissue contains .80% tumor.
Total RNA from 10–20 mg fresh frozen tissues were prepared
using the RNeasy midi kits (Qiagen, Valencia, CA) following
manufacturer’s instructions. After elution, RNA samples were
concentrated by EtOH precipitation at 220uC overnight, and
resuspended in nuclease-free water. Before labeling, RNA samples
were quantitated using a ND-1000 spectrophotometer (NanoDrop
Wilmington, DE) and evaluated for degradation using a 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Samples
were required to have a RIN .6.5, an OD 260:280 of 1.9–2.1, an
OD 260/230 .1.5 and .1.5 28S:18S ratio of the ribosomal
bands for gene expression array analysis.
Gene expression assay. Expression profiling was
accomplished using the HumanHT-12 v3 whole-genome gene
expression direct hybridization assay (Illumina, San Diego, CA) as
previously published [46]. Each array contains full-length 50-mer
probes representing more than 48,000 well-annotated RefSeq
transcripts, including .25,400 unique, curated, and up-to-date
genes derived from the National Center for Biotechnology
Information Reference Sequence (NCBI RefSeq) database (Build
36.2, Release 22). Initially, 250 ng total RNA was converted to
cDNA, followed by an in vitro transcription step to generate
labeled cRNA using the Ambion Illumina Total Prep RNA
Amplification Kit (Ambion, Austin, TX) as per manufacturer’s
instructions. The labeled probes were then mixed with
hybridization reagents and hybridized overnight to the
HumanHT-12 v3 BeadChips. Following washing and staining,
the BeadChips were imaged using the Illumina BeadArray Reader
to measure fluorescence intensity at each probe. The intensity of
the signal corresponds to the quantity of the respective mRNA in
the original sample. The expression profiles have been deposited
in NCBI’s Gene Expression Omnibus (GEO) with GSE accession
number GSE23518.
Data analysis. BeadChip data files are analyzed with
Illumina’s GenomeStudio gene expression module and R-based
Bioconductor package to determine gene expression signal levels
[47]. Briefly, the raw intensity of Illumina Human HT-12 v3.0
gene expression array was scanned and extracted using BeadScan,
with the data corrected by background subtraction in
GenomeStudio module. The lumi module in the R-based
Bioconductor Package was used to transform the expression
intensity into log2 scale [48]. The log2 transformed intensity data
were normalized using Quantile normalization function.
We used the Limma program in the R-based Bioconductor package
to calculate the level of differential expression [49]. Briefly, a linear
model was fit to the data (with cell means corresponding to the
different conditions and a random effect for array), and the list of
differentially expressed genes (DEGs) with Pvalue,0.01 were
obtained by performing the following comparisons based on
collected patients’ characteristics: USC stage (late vs. early), EAC
stage (late vs. early), USC prognosis (good vs. poor), and EAC
prognosis (good vs. poor).
Following single gene-based significance testing, we used the
expression value of DEGs (Pvalue,0.01) to cluster the patients for
each comparison. Our purpose was to determine whether the
identified DEGs for each comparison are able to serve as potential
gene signature to classify patients into their corresponding
clinicopathologic groups. Hierarchical clustering algorithm based
on the average linkage of Pearson Correlation was employed [50].
The DEGs were analyzed for enriched biological process terms
using the NCBI DAVID server (http://david.abcc.ncifcrf.gov)
with default setting [51]. All calculations were carried out under R
statistics computing.
Quantitative real time PCR analysis. The expression level
of 18 genes APLNR, CEBPA, CNTN1, ELF5, EPHA1, FBLN1,
FOSB, FST, HOXD10, KIF14, LMO4, LPAR2, NME3, NR2F1,
RASSF7, RHOBTB3, RPRM, TFF3 selected for validation was
determined using Taqman qRT-PCR gene expression Assay On
Demand Probe/Primers (Applied Biosystems, Foster City, CA),
with housekeeping gene GAPDH as an endogenous control.
Samples were run on the AB HT7900 Sequence Detection System
according to default parameters, with three replicate assays for
each gene in each sample. Using the RQ Manager Software 2.2.2
Gene Expression in Endometrial Carcinoma
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e15415(AB, Foster City, CA) the data was analyzed and the baseline and
the threshold were verified for each gene of interest. qRT-PCR
data were the normalized expression values in which the
housekeeping gene GAPDH was used as the reference gene. For
each assay, the average GAPDH Ct (Cycle threshold) value in the
TaqMan qPCR assay was subtracted from the Ct of gene of
interest to obtain a DCt value (gene of interest - GAPDH).
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